Seer Future App Download
Laurene Mallon
The time trend of mesothelioma incidence and projections of future cases provide useful information for analyzing proposed public health interventions where asbestos exposure may be an issue, evaluating regulatory proposals, and estimating the remaining potential costs of programs to compensate individuals with asbestos-related diseases. We used the April 2008 release of Surveillance, Epidemiology, and End Results (SEER) data, which covers 1973 through 2005, to analyze the time trends in age-adjusted mesothelioma incidence and to estimate an age and birth-cohort model to project the number of future mesothelioma cases. The increase in the number of SEER cancer registries from 13 to 17 in 2000 had little effect on the time pattern of age-adjusted mesothelioma incidence, and the pattern over time of pleural mesothelioma was indistinguishable from the pattern for total mesothelioma defined as sum of pleural and peritoneal cases. Our analysis suggests that the SEER registries viewed as a sample of the U.S. population over-represents high mesothelioma incidence, a fact that we accounted for in our projections. For 2008 we estimate approximately 2,400 cases, with asbestos the likely cause in 58%. We project that asbestos will no longer be a factor in mesothelioma cases after the year 2042. For 2008 through 2042, we estimate slightly more than 68,000 total cases, with asbestos the likely cause in 34%.
Intramembranous ossification involves the replacement of sheet-like connective tissue membranes with bony tissue. Bones formed in this manner are called intramembranous bones. They include certain flat bones of the skull and some of the irregular bones. The future bones are first formed as connective tissue membranes. Osteoblasts migrate to the membranes and deposit bony matrix around themselves. When the osteoblasts are surrounded by matrix they are called osteocytes.
Endochondral ossification involves the replacement of hyaline cartilage with bony tissue. Most of the bones of the skeleton are formed in this manner. These bones are called endochondral bones. In this process, the future bones are first formed as hyaline cartilage models. During the third month after conception, the perichondrium that surrounds the hyaline cartilage "models" becomes infiltrated with blood vessels and osteoblasts and changes into a periosteum. The osteoblasts form a collar of compact bone around the diaphysis. At the same time, the cartilage in the center of the diaphysis begins to disintegrate. Osteoblasts penetrate the disintegrating cartilage and replace it with spongy bone. This forms a primary ossification center. Ossification continues from this center toward the ends of the bones. After spongy bone is formed in the diaphysis, osteoclasts break down the newly formed bone to open up the medullary cavity.
Over the last fifty years, SEER has evolved with science and technology, becoming a better research resource with each advance. With its long-held commitment to progress, the future for SEER and the researchers who use it is bright.
time for a change!stream on other platforms - -------------------------------------------i know you got eyes onٰ mebut how much can you seeٰmr. future seer manwith a forwٰard thinking planwith a set of eyٰes on frontand a set of eyeٰs on backi don't know which waٰy to go,i don't know which way to gowill you always search forٰ metell me if you really seewhat it is that you're lookinٰg foris it worth it anymoreٰ?should i duck down on the floor? should i go out the front door?should i leave my room at all?are there eyes upon my wٰall?my house is filled with stuffgٰetting rٰid of it must be toughif you want to fix yourseٰlfyou might have to fix the sheٰlfwith all your memories onٰ displayhaven't moved since they were first placedand it's all just quite a messfor the mind it's kinda not the bestbut cleaning up a roomcan make you feel newopen up your eyes and see the real youmr future seer manwhat's your future seeing planare you only in my headare you still one step ahead?-------------------------------------------
The estimates of future incidence and burden in this study are the best assessment in light of current data. In particular, future prevalence rates of HBV, HCV, and obesity could alter these projections. Asian countries have some of the highest prevalence rates of HBV in the world.20 Compared with other racial/ethnic groups, APIs in the United States historically have had the highest HCC rates, which has been attributed to the high rates of HBV infection among older individuals born outside the United States.2 However, HCC rates among APIs have begun to decline in recent years.19 Although vaccination penetration still varies by country,21 in 1984 Taiwan became the first country to vaccinate newborns against HBV, and newborn HBV vaccination is now routine in many countries.2 Thus, the high HCC rates forecast among APIs in the 35- to 49-year-old age group (Data Supplement) do not fully account for the effect of HBV vaccination, although this can vary depending on country and geographic area (ie, rural v urban) of immigrant origin. We predict that HCC rates among APIs in this youngest age group may likely be much lower than what the model forecasts, which is based on the current cohorts of 35- to 49-year-olds, who would have been born before newborn HBV vaccination. In addition, HBV rates are high in sub-Saharan Africa, with estimates as high as 22.4% in South Sudan,20 and penetration of HBV vaccination remains low.21 However, African immigration remains low, with 4% of the foreign-born population reporting Africa as region of birth compared with 28.2% reporting Asia in 2010.22
Approximately 22% of HCC in the United States is attributed to HCV,23 and an estimated 1.60 million persons with HCV will be eligible for treatment between 2015 and 2020.24 The prior standard of care (SOC) for HCV was interferon-based therapy, which is associated with considerable toxicity.25 Second-generation direct-acting antivirals, including sofosbuvir, simeprevir, and sofosbuvir plus ledipasvir, were approved by the US Food and Drug Administration in 2013 and 2014.26-28 These treatments have a sustained virologic response rate of > 95% in most patients, are associated with fewer adverse effects than SOC therapy, and are given as a shorter course of treatment.29,30 It is estimated that, compared with the SOC, sofosbuvir-ledipasvir could prevent an additional 310 HCC cases per 10,000 treated HCV cases.24 However, these antivirals are expensive, with the per-patient cost of sofosbuvir-ledipasvir ranging from $66,000 to $154,000 depending on HCV genotype and treatment history.24 At a willingness-to-pay threshold of $100,000 per quality-adjusted life-year, sofosbuvir-based therapies were estimated to be cost effective in 83% of patients.24 However, this equates to $136 billion to treat all eligible patients with HCV with sofosbuvir-ledipasvir in the next 5 years, which is $65 billion more than the SOC, and the cost offsets (ie, reduced downstream costs from conditions such as HCC) would only be $16 billion.24 Although the American Association for the Study of Liver Disease and the Infectious Diseases Society of America recommend treatment of all HCV cases with antiviral therapy except those with a short life expectancy due to comorbidities, the cost of antiviral treatment precludes widespread delivery. Thus, the American Association for the Study of Liver Disease and the Infectious Diseases Society of America have recommended that antiviral therapy be prioritized for individuals with the most near-term need, that is, individuals at highest risk of substantial morbidity and mortality from untreated HCV infection, including individuals with advanced fibrosis or compensated fibrosis, transplant recipients, and those with severe extrahepatic manifestations.31 Although antivirals are currently prioritized for the most severe HCV infections, if treatment costs are reduced and antivirals can be administered to all persons presenting with HCV, this could have a notable impact on future HCC rates, as shown in our sensitivity analysis. However, cost of treatment is likely to remain a barrier to eradication of HCV for the foreseeable future.32,33
The concept of seid and völur or seeresses are known about from the Icelandic sagas, and their existence has also been confirmed by archaeological finds. Especially female graves, but also a few male burials, have been found containing unusual and strange items not typically found in Viking graves. These include special sticks or wands, intoxicants and unusual collections of small objects, such as owl pellets.
Nostradamus's father's family had originally been Jewish, but had converted to Catholic Christianity a generation before Nostradamus was born. He studied at the University of Avignon, but was forced to leave after just over a year when the university closed due to an outbreak of the plague. He worked as an apothecary for several years before entering the University of Montpellier, hoping to earn a doctorate, but was almost immediately expelled after his work as an apothecary (a manual trade forbidden by university statutes) was discovered. He first married in 1531, but his wife and two children died in 1534 during another plague outbreak. He fought alongside doctors against the plague before remarrying to Anne Ponsarde, with whom he had six children. He wrote an almanac for 1550 and, as a result of its success, continued writing them for future years as he began working as an astrologer for various wealthy patrons. Catherine de' Medici became one of his foremost supporters. His Les Prophéties, published in 1555, relied heavily on historical and literary precedent, and initially received mixed reception. He suffered from severe gout toward the end of his life, which eventually developed into edema. He died on 1 or 2 July 1566. Many popular authors have retold apocryphal legends about his life.